Biotech | January 11, 2022
Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Biogen paid Ionis a US $ 60 million one-time upfront payment
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
Tangent offers ISO/IEC 17025-accredited calibrations and has labs located in both Indianapolis and Huntsville, Alabama
The first pilot study from India analyzing Covaxin-Covishield mixed doses
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Subscribe To Our Newsletter & Stay Updated
